| Literature DB >> 34490082 |
Yu Zhang1,2, Kewei Liang2,3,4, Jiaqi He2,5, He Ma4, Hongyan Chen1, Fei Zheng1, Lingling Zhang1, Xinsheng Wang6, Xibo Ma2,3, Xuzhu Chen1.
Abstract
OBJECTIVES: To explore the MRI-based differential diagnosis of deep learning with data enhancement for cerebral glioblastoma (GBM), primary central nervous system lymphoma (PCNSL), and tumefactive demyelinating lesion (TDL).Entities:
Keywords: deep learning; differential diagnosis; glioblastoma; lymphoma; tumefactive demyelination
Year: 2021 PMID: 34490082 PMCID: PMC8416477 DOI: 10.3389/fonc.2021.665891
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Figure 1The implementation process of three-stage algorithm based on deep learning with data enhancement. In the first stage, 3D u-net is used to capture the lesion area; in the second stage, enhanced data are generated; and in the third stage, 3D Resnet is used for diagnosis.
Figure 2Enhanced data with different k values. The top row represents solitary figures, and the bottom row represents multiple lesions. k is −0.5 (A), 0 (B), 0.5 (C), 1 (D), and 2 (E).
Figure 3The implementation process of the lesion area diagnosis algorithm.
Clinical characteristics of subjects.
| GBM | PCNSL | TDL |
| |
|---|---|---|---|---|
| Number of subjects | 97 | 92 | 72 | |
| Age (years, mean ± SD) | 54.61 ± 12.35 | 53.34 ± 12.57 | 41.33 ± 12.82 | <0.001* |
|
| 0.224 | |||
| Male | 56 (57.7%) | 57 (62.0%) | 35 (48.6%) | |
| Female | 41 (42.3%) | 35 (38.0%) | 37 (51.4%) | |
| Number of lesions | <0.001* | |||
| Solitary | 83 (85.6%) | 45 (48.9%) | 32 (44.4%) | |
| Multiple | 14 (14.4%) | 47 (51.1%) | 40 (55.6%) |
*p < 0.05. GBM, cerebral glioblastoma; PCNSL, primary central nervous system lymphoma; TDL, tumefactive demyelinating lesion; SD, standard deviation.
Diagnostic performance at different k values.
| k | Overall accuracy | AUC (95% CI) | ACC | SEN | SPE | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GBM | PCNSL | TDL | GBM | PCNSL | TDL | GBM | PCNSL | TDL | GBM | PCNSL | TDL | ||
| –0.5 | 0.81 | 1.00 (1.000–1.000) | 0.86 (0.785–0.943) | 0.83 (0.738–0.924) | 1.00 | 0.81 | 0.81 | 1.00 | 0.82 | 0.55 | 1.00 | 0.81 | 0.91 |
| 0 | 0.86 | 1.00 (1.000–1.000) | 0.92 (0.856–0.980) | 0.90 (0.823–0.975) | 1.00 | 0.86 | 0.86 | 1.00 | 0.82 | 0.73 | 1.00 | 0.88 | 0.91 |
| 0.5 | 0.92 | 1.00 (1.000–1.000) | 0.96 (0.923–1.000) | 0.95 (0.904–1.000) | 1.00 | 0.92 | 0.92 | 1.00 | 0.85 | 0.91 | 1.00 | 0.96 | 0.93 |
| 1 | 0.91 | 1.00 (1.000–1.000) | 0.95 (0.900–1.000) | 0.92 (0.838–1.000) | 1.00 | 0.91 | 0.91 | 1.00 | 0.85 | 0.86 | 1.00 | 0.94 | 0.93 |
| 2 | 0.92 | 1.00 (1.000–1.000) | 0.96 (0.906–1.000) | 0.92 (0.813–1.000) | 1.00 | 0.92 | 0.92 | 1.00 | 0.85 | 0.91 | 1.00 | 0.96 | 0.93 |
AUC, area under the curve; ACC, accuracy; SEN, sensitivity; SPE, specificity; GBM, cerebral glioblastoma; PCNSL, primary central nervous system lymphoma; TDL, tumefactive demyelinating lesion.
Diagnostic performance of the model using the lesion area.
| AUC (95% CI) | ACC | SEN | SPE | |
|---|---|---|---|---|
| GBM | 1.00 (1.000–1.000) | 1.00 | 1.00 | 1.00 |
| PCNSL | 0.94 (0.900–0.989) | 0.84 | 0.70 | 0.90 |
| TDL | 0.94 (0.892–0.991) | 0.84 | 0.77 | 0.86 |
| Overall accuracy | 0.84 |
AUC, area under the curve; ACC, accuracy; SEN, sensitivity; SPE, specificity; GBM, cerebral glioblastoma; PCNSL, primary central nervous system lymphoma; TDL, tumefactive demyelinating lesion.
Figure 4Receiver operating characteristic (ROC) curve at different k values and region of interest (ROI).
Figure 5The selected radiomics features of GBM, PCNSL, and TDL at the optimal k value.